China Offers Level Field In Trade Pact Bid But Multiple Pharma Barriers Remain
Provincial Schemes, Security Concerns Still Challenging
Executive Summary
China has signaled that it will offer a more level playing field to foreign players as part of a bid to join a major regional trade pact but some see the gesture as offering little real relief and high hurdles remain.
You may also be interested in...
Novo Nordisk Braced For China Insulin Scheme Impact
The value-based procurement scheme in China is about to be implemented on insulin products and while most of Novo Nordisk's therapies were included in the tender, price cuts are going to impact global sales growth by 3% next year.
Chinese Firms Bag Most Latest Volume-Based Purchasing Wins
Domestic companies have won most of the bids in China's latest government procurement round for 62 drugs, marking an end to the previous dominance of off-patent products from multinationals.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.